Studies on the immunosuppressive properties of cyclosporin a in rats receiving renal allografts

W P HomanP J Morris


The immunosuppressive effects of cyclosporin A were tested in a DA (RT-1a) to Lewis (RT-1(1) rat renal allograft model, which represents a very strong histocompatibility barrier. Dose-response studies established that oral doses of 5 mg/kg/day or higher gave complete suppression of rejection, while oral doses of 2 mg/kg/day or lower were without effect. Intravenous administration of the drug approximately doubled its potency. Time studies showed that the period of administration was also critical, with a 7- or 14-day treatment course with 5 mg/kg/day orally giving prolonged graft survival, while a 4-day course was without effect. Large doses (up to 25 mg/kg/day orally) from day 4 after transplantation did not prolong graft survival, suggesting that cyclosporin A has no effect on an established rejection response. It was found that the lymphocytotoxin response to the graft was markedly suppressed by doses of cyclosporin A which maintained normal graft function, while lower doses had little or no effect on the lymphocytotoxin response. A cell-mediated immunity assay showed a substantial response, but one that was lower in amplitude from that of control animals. Histological study of 7th day allograft biopsies demonstrated essenti...Continue Reading


Apr 1, 1984·World Journal of Surgery·D W Gray, P J Morris
Jun 1, 1986·World Journal of Surgery·D W Gray, P J Morris
Jan 1, 1985·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·T S LieH Nakano
Oct 1, 1984·Agents and Actions·A W ThomsonJ G Simpson
Sep 1, 1984·The Journal of Surgical Research·F E JohnsonD R Herbold
Jan 1, 1983·International Journal of Immunopharmacology·G Pawelec, P Wernet
Jan 1, 1987·International Journal of Immunopharmacology·S C ThompsonR C Burton
Jun 9, 1998·Developmental and Comparative Immunology·S Tozaki, S Tochinai
Dec 1, 1983·The Journal of Experimental Medicine·N KaibaraI Katsuki
May 1, 1984·The Journal of Experimental Medicine·N KaibaraS Jingushi
Sep 1, 1993·Clinical and Experimental Immunology·J M WangM Laviolette
Jul 23, 1998·Clinical and Experimental Pharmacology & Physiology·H YamauchiA Fujimura
Jan 1, 1991·Diabetic Medicine : a Journal of the British Diabetic Association·K FederlinB J Hering
Jun 1, 1993·Immunological Reviews·P GianelloD H Sachs
Apr 1, 1987·Journal of Veterinary Internal Medicine·C R GregoryJ D Patz
Apr 1, 1986·Annals of the Rheumatic Diseases·K TakagishiK Arai
Jul 1, 1985·Journal of Neurology, Neurosurgery, and Psychiatry·E R FeringaW J Gilbertie
Sep 1, 1986·The Laryngoscope·M Friedman
Jan 27, 1998·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·R G ErbenR Gärtner
Apr 1, 1984·World Journal of Surgery·D F du ToitE A van der Merwe
Nov 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A P Provoost
Jan 1, 1989·Kidney International·T M CoffmanP E Klotman
May 1, 1981·Immunology Today·G G Klaus
Apr 1, 1986·Immunology Today·G G Klaus, P M Chisholm
Aug 1, 1982·Experimental Neurology·A K Gulati, A A Zalewski
Jun 1, 1989·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·P OrcelM C de Vernejoul
Jan 1, 1985·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·S B WarrenG E Friedlaender
Oct 1, 1985·European Journal of Immunology·P M ChisholmW L Ford
Oct 1, 1982·The Journal of Pathology·J T BlairJ G Simpson
Jan 1, 1980·Immunological Reviews·P J Morris
Dec 15, 1981·Biochemical Pharmacology·M J Farthing, M L Clark
Oct 14, 2014·Frontiers in Aging Neuroscience·Francesca GattazzoPaolo Bonaldo
Jul 13, 2007·Acta Cirúrgica Brasileira·Antonio Chiquetti JúniorVinicius Daher Alvares Delfino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.